Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.","authors":"Marion Graf, Michael Gerken, Monika Klinkhammer-Schalke, Simone Schrodi, Armin Pauer, Karla Geiss, Olaf Ortmann, Elisabeth C Sturm-Inwald","doi":"10.1007/s00432-025-06220-y","DOIUrl":"https://doi.org/10.1007/s00432-025-06220-y","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the present study was to compare patient, tumor characteristics and prognostic factors as well as diagnostics and therapies between men and women with breast cancer. The rates of primary distant metastases, contralateral second tumors, overall survival (OS), recurrence, and recurrence-free survival (RFS) were analyzed and compared between men and women.</p><p><strong>Methods: </strong>This retrospective cohort study included patient data from 18 clinical cancer registries in Germany (2000-2018). Differences in risk factors and short-term endpoints were analyzed via univariable and multivariable binary logistic regression analyses. OS, RFS, and the rate of subsequent second tumors were examined via Kaplan‒Meier, univariable and multivariable Cox regression methods.</p><p><strong>Results: </strong>Compared with women, male patients with breast cancer presented a significantly greater risk of unfavorable prognostic factors, such as advanced stage, lymphatic invasion, and more primary distant metastases. While sentinel lymph node biopsy and HER-2 testing were comparable, treatment rates for men were 9.5-29.0% lower than those for women. In multivariable analyses, men had a 1.32-fold increased risk of death (95% CI 1.24-1.41; p < 0.001). The risk of recurrence/mortality was significantly increased by a factor of 1.531 (95% CI 1.43-1.65; p < 0.001). Adjustment for therapy in a multivariable regression model did not significantly affect the risk of death. Nevertheless, men had a survival benefit from systemic therapies comparable to that of women.</p><p><strong>Conclusion: </strong>Neither patient and tumor characteristics nor differences in therapy could completely explain the difference in mortality between men and women. Differences in lifestyle or biological factors could play a role.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"181"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prognostic PET radiomic model for risk stratification in non-small cell lung cancer: integrating radiogenomics and clinical features to predict survival and uncover tumor biology insights.","authors":"Parisa Taheri, Aaron Golden","doi":"10.1007/s00432-025-06232-8","DOIUrl":"https://doi.org/10.1007/s00432-025-06232-8","url":null,"abstract":"<p><strong>Purpose: </strong>To develop a survival risk score using ¹⁸F-FDG PET radiomic features for non-small cell lung cancer (NSCLC) patients and to evaluate its biological basis as a prognostic radiomic signature through radiogenomic analyses.</p><p><strong>Methods: </strong>We utilized several NSCLC cohort datasets from the Cancer Imaging Archive (TCIA) for radiomic analysis, where transcriptomics data were available through the Cancer Genome Atlas (TCGA). A total of 945 radiomic features were extracted from the segmented tumors. A survival-based radiomic model was developed, from which a radiomic risk score was calculated. Radiogenomic analyses were then performed to explore correlations between radiomic risk cohorts and tumor transcriptomics, oncogenic pathways, and genetic mutations. We also constructed a nomogram by combining clinical and radiomic risk factors.</p><p><strong>Results: </strong>The PET-radiomic model significantly predicted the 5-year survival rate of patients, with AUCs of 0.78, 0.71, and 0.73 in the training, validation, and testing cohorts, respectively. Integration of clinical features and the radiomic risk score in a nomogram demonstrated enhanced efficacy, achieving AUCs greater than 0.85. Radiogenomic analysis revealed that while the low-risk group indicated anti-tumor immunity, the high-risk group exhibited transcriptomic characteristics associated with enhanced tumor aggressiveness, with consistent correlations between risk group membership, oncogenic pathways, immune cell types, and critical gene alterations.</p><p><strong>Conclusion: </strong>PET-radiomic features successfully delineated high- and low-risk NSCLC patient groups. Supporting radiogenomic analysis identified tumor-promoting characteristics and immune-suppressing activity in the high-risk group, which is consistent with these patients' prognoses.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"180"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment evaluation in patients with SMARCA4-deficient tumors: case reports of four patients.","authors":"Xueqin Zhao, Wei Fu","doi":"10.1007/s00432-025-06207-9","DOIUrl":"https://doi.org/10.1007/s00432-025-06207-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to characterize SMARCA4-deficient tumors using ¹⁸F-FDG PET/CT and explore its role in diagnosis, staging, therapeutic response assessment, and prognosis across multiple pathological subtypes.</p><p><strong>Methods: </strong>We retrospectively analyzed four patients with histologically confirmed SMARCA4-deficient tumors. Clinical features, ¹⁸F-FDG PET/CT findings, pathological subtypes, molecular characteristics, treatment modalities, and outcomes were evaluated.</p><p><strong>Results: </strong>All tumors demonstrated high FDG uptake, indicating elevated metabolic activity. Imaging patterns varied by subtype, including undifferentiated carcinoma and non-small cell lung cancer. Treatment strategies involved chemotherapy, immunotherapy, and targeted therapy with diverse responses. SMARCA4 deficiency was associated with poor prognosis and potential treatment resistance.</p><p><strong>Conclusion: </strong>¹⁸F-FDG PET/CT is valuable in the comprehensive assessment of SMARCA4-deficient tumors. Combined with molecular profiling, it enhances diagnostic accuracy and aids in individualized treatment planning. This case series offers preliminary guidance for clinicians managing this rare, aggressive tumor type.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"182"},"PeriodicalIF":2.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis.","authors":"Shaurya Dhingra, Matthew Koshy, Mark Korpics","doi":"10.1007/s00432-025-06171-4","DOIUrl":"https://doi.org/10.1007/s00432-025-06171-4","url":null,"abstract":"<p><strong>Background: </strong>The EF14 clinical trial reported an improvement in median overall survival (OS) from 16.0 months to 20.9 months in patients with glioblastoma (GBM) who received treatment with tumor treating fields (TTFs). This study evaluates overall survival in a large population-based cohort of patients with GBM before and after FDA approval of TTFs in 2015.</p><p><strong>Methods: </strong>A total of 27,534 patients from the Surveillance, Epidemiology and End Results (SEER) database with GBM who underwent surgery and post-operative radiotherapy were grouped into three diagnosis periods: those diagnosed pre-temozolomide (2000-2004), those diagnosed post-temozolomide (2005-2015), and those diagnosed post-TTFs (2016-2020). Overall survival (OS) was calculated using the Kaplan-Meier method, and multivariate Cox regression models were employed to estimate hazard ratios (HR).</p><p><strong>Results: </strong>GBM diagnosis in the post-TTFs period was associated with a median OS of 15 months (95% CI 14-15 months) compared to a median OS of 14 months (95% CI 14-14 months, p < 0.001) for GBM diagnosis in the post-temozolomide/pre-TTFs period. 24-months OS was 25.6% (95% CI 24.5-26.8%) in the post-TTFs period and 24.7% (95% CI 24.0-25.4%) in the post-temozolomide/pre-TTFs period. In a multivariate model accounting for clinical characteristics, diagnosis in the post-TTFs period as compared to the post-temozolomide/pre-TTFs period was significantly associated with OS (HR: 0.941, 95% CI 0.912-0.972, p < 0.001).</p><p><strong>Conclusion: </strong>This population-based cohort demonstrated minimal change in survival for patients diagnosed with GBM before and after FDA approval of TTFs in 2015.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"179"},"PeriodicalIF":2.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome in prostate cancer: pathogenic mechanisms, multi-omics diagnostics, and synergistic therapies.","authors":"Chengran Wang, Tianqi Dong, Xin'ao Rong, Yuce Yang, Jianhui Mou, Jiaqi Li, Jianli Ge, Xupeng Mu, Jinlan Jiang","doi":"10.1007/s00432-025-06187-w","DOIUrl":"10.1007/s00432-025-06187-w","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is a leading cause of cancer-related deaths in men, with the microbiome emerging as a significant factor in its development and progression. Understanding the microbiome's role could provide new insights into PCa pathogenesis and treatment.</p><p><strong>Objective: </strong>This review aims to explore the interactions between the microbiome and PCa, focusing on microbial imbalances and their effects on immune responses, inflammation, and hormone levels. It also discusses advanced research techniques and the potential for microbiome modulation in PCa management.</p><p><strong>Methods: </strong>The review synthesizes current literature on the microbiome's role in PCa, highlighting differences in microbial composition between cancerous and healthy prostate tissues. It examines techniques such as high-throughput sequencing and metagenomics and explores the mechanisms through which the microbiome influences PCa.</p><p><strong>Conclusions: </strong>The review reveals substantial microbial differences in prostate tissues of PCa patients compared to healthy individuals, indicating a potential link between microbiome alterations and disease progression. It highlights the promise of microbiome-based strategies for diagnosis and treatment and underscores the need for further research into personalized, microbiome-centric approaches for PCa management.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 6","pages":"178"},"PeriodicalIF":2.7,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life after risk reducing mastectomy in a Portuguese cohort of BRCA pathogenic/likely pathogenic variant carriers.","authors":"Maria Raposo, Bárbara Peleteiro, André Magalhães, Sandra Torres, Inês Insua-Pereira, Raquel Guimarães, Luzia Garrido, Susy Costa, José Luis Fougo","doi":"10.1007/s00432-025-06231-9","DOIUrl":"10.1007/s00432-025-06231-9","url":null,"abstract":"<p><strong>Purpose: </strong>Women with pathogenic/likely pathogenic (P/LP) variants in BRCA1/2 genes have an increased lifetime risk of breast and ovarian cancer. Cancer risk management options include intensive breast surveillance (IBS) and risk reducing mastectomy (RRM). This study aims to compare the effect of these strategies on quality of life, anxiety, and depression to enhance shared decision-making.</p><p><strong>Methods: </strong>We retrospectively analysed clinical records of 221 women with P/LP variants in BRCA1/2 genes, from 2007 to 2024. A total of 169 questionnaires containing Hospital Anxiety and Depression Scale (HADS) and BREAST-Q were sent, from May to September 2024. Ninety-nine women, 48 who had undergone RRM and 51 who had opted for IBS, completed the questionnaires. Patient-reported outcome measures (PROMs) were compared based on their choice.</p><p><strong>Results: </strong>Significant differences were found in age at genetic testing and personal history of breast cancer between the groups. In BREAST-Q, the IBS group reported higher scores, with statistically significant differences for Satisfaction with Breasts and Physical Well-Being: Chest. These differences were only observed in the group of women without personal breast cancer history who underwent RRM.</p><p><strong>Conclusions: </strong>No significant differences were found in psychologic distress levels between the IBS and RRM group. Although RRM is an effective method for reducing breast cancer risk in women with P/LP variants in BRCA1/2 genes, carriers should be informed of its impact on quality of life. Notably, once a woman is diagnosed with breast cancer, these differences lose effect.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"177"},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective comprehensive analysis of regional lymph node recurrence in breast cancer patients (REASON study).","authors":"Aikaterini Liapi, Veronica Aedo-Lopez, Wendy Jeanneret-Sozzi, Athina Stravodimou, John O Prior, Marie Nicod Lalonde, Assia Ifticene Treboux, Loic Lelievre, Lana Kandalaft, Laetitia Rossier, Audrey Goupil, Marzio Bergomi, Jean-Paul Rivals, Jean-Philippe Brouland, Elsa Curtit, Jean-Yves Meuwly, Khalil Zaman","doi":"10.1007/s00432-025-06235-5","DOIUrl":"10.1007/s00432-025-06235-5","url":null,"abstract":"<p><strong>Background: </strong>Randomized trials have progressively enabled the de-escalation of axillary surgery in breast cancer (BC) patients, reducing adverse events without compromising survival. Despite a not negligible rate of residual disease in the axilla after sentinel lymph node (SLN) procedure, the risk of regional lymph node recurrence (RLNR) is very low, due probably to multimodal adjuvant treatments. The characteristics of the small number of patients with RLNR remain poorly characterized and warrant further investigation, especially given their poor prognosis and the current context of ongoing studies exploring further de-escalation of axillary surgery.</p><p><strong>Methods: </strong>In this retrospective and single institution study, we analyzed thoroughly a cohort of patients who experienced RLNR as first event between 2009 and 2020. MammaPrint and BluePrint analysis (MB) was performed in available primary invasive cancer tissues.</p><p><strong>Results: </strong>Forty patients, median age of 52, were analyzed. Disease-free interval was 8.7 years. Most of the patients (65%) had no special type BC. Majority (73%) had hormone receptor positive-HER2 negative (HR + /HER2-) BC, 13% triple negative (TNBC), 6% HER2 + , 8% ductal carcinoma in situ and 3% unknown. The median size of the primary tumor was 1.8 cm (range 0.3-7.0) and 57% had no initial LN involvement. Forty five percent had primary SLN procedure and 53% axillary LN dissection (ALND) of the patients received neo-/adjuvant chemotherapy, 63% endocrine therapy and 68% radiotherapy (50% only in breast). Sixty three percent had only RLNR and 38% had concomitant distant metastases. Among irradiated patients, 63% had some relapse in the radiation field. The MB analysis classified 70% of the analyzed cancers as low-risk luminal A (82% in HR + /HER2-), 15% high-risk luminal B, 10% high-risk basal type, and 5% high-risk HER2 type.</p><p><strong>Conclusion: </strong>Our study confirms that patients treated with SLN do not show a higher risk of LRNR compared to ALND. LRNR is often diagnosed incidentally. Younger age, residual disease post-NAC, no regional radiation, stage II, and initial LN involvement were more represented, as well as patients with endocrine sensitive disease classified as low-risk luminal A by MB. Ongoing trials, including SOUND, INSEMA, and BOOG 2013-08, are further exploring axillary surgery de-escalation.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"176"},"PeriodicalIF":2.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant chemotherapy may have no significant survival benefit in older patients with stage II/III gastric cancer: a multicenter retrospective study.","authors":"Zheng-Zheng Shen, En-Ze Li, Ruo-Lan Zhang, Meng-Xuan Cao, Yan-Qiang Zhang, Qing Yang, Can Hu, Si-Wei Pan, Zhi-Yuan Xu, Zai-Sheng Ye, Jing-Yang He","doi":"10.1007/s00432-025-06230-w","DOIUrl":"10.1007/s00432-025-06230-w","url":null,"abstract":"<p><strong>Aim: </strong>Postoperative adjuvant chemotherapy is known to enhance cure rates and is thus recommended for stages pII to pIII. However, specific guidelines for such treatment in elderly gastric cancer (GC) patients are currently lacking. This study examines the impact of adjuvant chemotherapy on the postoperative survival of these patients.</p><p><strong>Methods: </strong>We reviewed a total of 7749 patients with GC who underwent radical gastrectomy at Zhejiang Cancer Hospital and Fujian Cancer Hospital from January 2007 to December 2019. We conducted univariate and multivariate Cox regression analyses to investigate the impact of clinicopathological factors on overall survival (OS) and cancer-specific survival (CSS) in these patients. Additionally, we created a meta-analysis forest plot and employed propensity score matching (PSM) to mitigate confounding bias.</p><p><strong>Results: </strong>Age and adjuvant chemotherapy were independent risk factors for OS and CSS. Stratified analysis based on chemotherapy use revealed a statistically significant difference in OS and CSS between younger patients who did and did not receive adjuvant chemotherapy. In contrast, no significant differences in OS and CSS were observed between older patients with or without adjuvant chemotherapy. These findings remained consistent after propensity score matching (PSM).</p><p><strong>Conclusions: </strong>Age and adjuvant chemotherapy are independent risk factors for OS and CSS in patients with stage II/III GC; for patients with stage II/III gastric cancer aged ≥ 75 years, shared decision-making should be made taking into account functional status and comorbidities, rather than conventional adjuvant chemotherapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"175"},"PeriodicalIF":2.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy.","authors":"Chandrashekar Mataguru Doreswamy, Srinivas Seekallu, Suresh Babu Venkataramaiah, Mohan Cheluru Umesh, C Subathra Devi","doi":"10.1007/s00432-025-06227-5","DOIUrl":"10.1007/s00432-025-06227-5","url":null,"abstract":"<p><strong>Background: </strong>Histone deacetylases (HDAC) are involved in chromatin remodelling, and histone deacetylases inhibitors have become the interest of research and shown promising antitumor effects against various cancer.</p><p><strong>Methods: </strong>In the current study, an attempt was made to characterize the preclinical ADME properties of a novel hydroxamic based HDAC inhibitor, PAT-1102, with the help of in vitro assays and in vivo pharmacokinetic experiments in rats.</p><p><strong>Results: </strong>PAT-1102 showed high aqueous solubility and high Caco-2 permeability in the in vitro assays. It was found to be not a substrate of efflux protein P-gp, found stable in metabolism experiments with incubations of rat and human liver microsomes. Inhibition experiments of human recombinant CYP enzymes revealed that PAT-1102 was not considerably inhibited the major CYP enzymes. PAT-1102 exhibited low plasma protein binding of 58.1% and 54.5% in humans and rats, respectively. In vivo pharmacokinetic studies of PAT-1102 in male and female rats showed bioavailability of 3.7% and 3.0% by oral route, respectively. Previous research findings suggested that PAT-1102 is a potent pan-HDAC inhibitor with good preclinical efficacy.</p><p><strong>Conclusion: </strong>Considering the overall ADME and pharmacokinetic profile of PAT-1102, as indicated by in vitro and in vivo experiments, the PAT-1102 could be considered as a potential candidate for the advancement of cancer therapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"174"},"PeriodicalIF":2.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis.","authors":"Lijie Liang, Xue Meng, Li Xie, Na Li, You Feng, Ming Jiang","doi":"10.1007/s00432-025-06205-x","DOIUrl":"10.1007/s00432-025-06205-x","url":null,"abstract":"<p><strong>Purpose: </strong>Primary central nervous system lymphoma (PCNSL) has a poor prognosis, mainly because of the significant challenges with the efficacy and tolerability of induction chemotherapy. This retrospective study aimed to evaluate the efficacy and safety of the R2-MTX regimen in PCNSL patients.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 39 PCNSL patients treated with the R2-MTX regimen, focusing on treatment outcomes and adverse events (AEs).</p><p><strong>Results: </strong>The overall response rate (ORR) was 72.2%, with a complete response (CR) rate of 69.4% and a partial response (PR) rate of 2.8%. With a median follow-up of 37.2 months (interquartile range [IQR] 24.2-47.5), the estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 54.9% (95% CI, 37.2-69.5%) and 78.5% (95% CI, 59.8-89.2%), respectively. The most common grade 3 or 4 AEs included neutropenia (33.3%), leukopenia (13.9%), anemia (2.8%), and thrombocytopenia (2.8%). Consolidation or maintenance therapy was associated with prolonged survival in PCNSL patients (2-year OS rates 100% vs. 42.9%, P = 0.067). Survival analysis revealed that clinicopathological factors, such as double-expressor lymphoma (DEL), ECOG PS ≥ 2, and high-risk classification based on the Memorial Sloan Kettering Cancer Center model (MSKCC), predicted poor survival.</p><p><strong>Conclusions: </strong>Our results underscore the therapeutic potential of the R2-MTX regimen in managing newly diagnosed PCNSL patients. Further prospective studies with larger patient cohorts are imperative to solidify these preliminary findings.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"173"},"PeriodicalIF":2.7,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}